Michael F. Saulino, MD, PhD
Department of Physical Medicine and Rehabilitation
Jefferson Medical College, Thomas Jefferson University
Elkins Park, Pennsylvania
David M. Simpson, MD
Professor of Neurology
Director, Clinical Neurophysiology Laboratories
Director, Neuromuscular Division
Mount Sinai Medical Center
New York, New York
Spasticity is a common chronic condition that is estimated to affect over half a million persons in the US. The etiologies of spasticity are heterogeneous and include neurologic disorders such as cerebral palsy and multiple sclerosis, as well as physical insults to the central nervous system seen with strokes and traumatic brain injuries. Treating spasticity requires ongoing management, which can include a number of different treatments given over many years. The goal of this continuing medical education activity is to help clinicians understand the appropriate use of current and evolving therapies for spasticity and, ultimately, to improve outcomes for their patients with this condition.
Temple University School of Medicine and MCM Education
Neurologists, physiatrists, and other clinicians who treat patients with spasticity.
Upon completion of this educational activity, the participant should be able to:
Discuss how to best assess patients with spasticity and determine the best treatment strategies.
Review treatment options for patients with spasticity.
Describe the role of botulinum neurotoxins in treating patients with spasticity.
It is the policy of Temple University School of Medicine; The Albert J. Finestone, MD Office for Continuing Medical Education to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored or jointly sponsored educational programs. All faculty, program planning committee members, and Temple University School of Medicine Continuing Medical Education staff participating in programs sponsored or jointly sponsored by Temple University School of Medicine are expected to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation(s).
Planning committee members have no financial relationships to disclose.
Dr. Saulino discloses that he has received grant/research funding from Medtronic and has served on speakersí bureaus for Medtronic, Azur, and Ipsen.
Dr. Simpson discloses that he has received grant/research funding from Allergan, Merz, Ipsen, and US Worldmeds; has served as a consultant for Allergan, Merz, Ipsen, US Worldmeds, and Acorda; and has served on speakersí bureaus for Allergan, US Worldmeds, and Merz.
Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor Continuing Medical Education for physicians.
Temple University School of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
There is no fee to participate and receive credit. Commercial Support Statements
This activity is supported by an educational grant from Ipsen.
The information presented in this CME monograph represents the views and opinions of the individual authors, and does not constitute the opinion or endorsement of, or promotion by, Temple University School of Medicine, Temple University Health System or its affiliates. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each participant must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.